This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
The technique aims to treat some diseases by gene replacement.
-
Peter Marks Director CBER, FDA
-
P.J. Brooks Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
Cyber Resilience and Recovery Amid Evolving Cyber Threats
Data durability is a key aspect of NIST’s cybersecurity framework for public and private organizations.
21m listen -
How Tech Enables Environmental Justice at EPA
The agency wants to eliminate bias and establish new tech standards to reduce greenhouse gas emissions.
39m listen -
Building Better Data Governance Across FDA
The agency is using emerging technology to tackle its data challenges.
19m listen -
Coast Guard Poised for Growth in Cyber
The service’s prevention policy chief discusses his priorities for combatting cyber incidents that could have global impacts.
23m listen